Clinical study of tiotropium combined with moxifloxacin in treatment of acute exacerbation of mild to moderate chronic obstructive pulmonary disease
Objective To investigate the clinical efficacy of tiotropium combined with moxifloxacin in treatment of acute exacerbation of mild to moderate chronic obstructive pulmonary disease.Methods Data of 78 patients with acute exacerbation of mild to moderate chronic obstructive pulmonary disease admitted to the Respiratory Department of Pinggu Hospital,Beijing Friendship Hospital Affiliated to Capital Medical University from December 2019 to November 2022 were retrospectively collected.According to different treatment plans,the patients were divided into control group and treatment group,with 39 cases in each group.Patients in the control group were iv administered with Moxifloxacin Hydrochloride and Sodium Chloride Injection,0.4 g/time,each infusion time≥90 min.Patients in the treatment group were given Tiotropium Bromide Powder for inhalation on the basis of the control group,1 capsule/time,and the drug delivery device was inhaled through a powder mist inhaler,once daily.The two groups were treated for 10 d.The clinical efficacy of the two groups was observed.The scores of Cough and Sputum Assessment Questionnaire(CASA-Q)score,blood gas analysis indexes,modified Medical Research Council Dyspnea Questionnaire(mMRC)score,peripheral blood neutrophil to lymphocyte ratio(NLR),platelet to lymphocyte ratio(PLR)and serum C-reactive protein(CRP)were compared between the two groups before and after treatment.Results After treatment,the total effective rate of the treatment group was 97.44% ,which was significantly higher than that of the control group(79.49% )(P<0.05).After treatment,the scores of cough symptoms,cough effects,sputum symptoms,sputum effects and total scores of CASA-Q in 2 groups were significantly increased compared with those before treatment(P<0.05).After treatment,the CASA-Q score in the treatment group was higher than that in the control group(P<0.05).After treatment,the arterial partial pressure of oxygen(pO2)increased significantly,while the arterial partial pressure of carbon dioxide(pCO2)decreased significantly in both groups(P<0.05).After treatment,the blood gas index in the treatment group was better than that in the control group(P<0.05).After treatment,mMRC scores in both groups were significantly decreased(P<0.05).After treatment,the mMRC score of the treatment group was lower than that of the control group(P<0.05).After treatment,the levels of peripheral blood NLR,PLR,and serum CRP in both groups were significantly decreased(P<0.05).After treatment,the levels of NLR,PLR,and serum CRP were significantly decreased in the treatment group(P<0.05).Conclusion Tiotropium combined with moxifloxacin has a good therapeutic effect in treatment of acute exacerbation of mild to moderate chronic obstructive pulmonary disease,and can safely and effectively relieve respiratory symptoms,improve arterial blood gas and lung function,which can regulate the inflammatory state of the body.
Tiotropium Bromide Powder for inhalationMoxifloxacin Hydrochloride and Sodium Chloride Injectionacute exacerbation of chronic obstructive pulmonary diseasepO2CASA-Q scoreNLRPLRCRP
NETL
NSTL
万方数据
维普
